Autonomix Highlights Podium-Selected Data on Visceral Cancer Pain and Pancreatic Feasibility
AMIX•Autonomix Medical highlighted podium clinical data at the Society of Surgical Oncology Annual Meeting in a Virtual Investor segment led by City of Hope’s Dr. Toufic Kachaamy. He detailed the catheter-based microchip platform’s differentiated visceral cancer pain management, pancreatic cancer feasibility and broader peripheral nervous system applications.
1. Virtual Investor Segment Participation
Autonomix Medical took part in a Virtual Investor “What This Means” segment featuring Dr. Toufic Kachaamy, Chief of Medicine at City of Hope, to discuss recent clinical data selected for a podium presentation at the Society of Surgical Oncology Annual Meeting.
2. Clinical Data Highlights
Dr. Kachaamy reviewed data on Autonomix’s catheter-based microchip sensing array, emphasizing its differentiated approach to visceral cancer pain management and initial feasibility findings in pancreatic cancer patients.
3. Platform Potential and Future Applications
The technology’s ability to detect and differentiate neural signals with greater sensitivity supports potential expansion into peripheral nervous system indications such as cardiology, hypertension and chronic pain management, bolstering ongoing clinical development.
